Death rates from heart disease and stroke are falling in-part because of new drug treatments. According to the National Heart, Lung and Blood Institute, if death rates were the same… [ Get More Details ]
Cost-effectiveness of TAVR in sSAS patients
Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY… [ Get More Details ]
Following the current path, pulmonary condition cases will increase by 31.3% between 2003 and 2023. If an alternative path is taken, there will be 9.1% fewer pulmonary condition cases.
[ Get More Details ]